Daniel Morgenstern is a Staff Oncologist at Hospital for Sick Children, Toronto and Associate Professor at the University of Toronto. He originally trained and worked in the UK, primarily at Great Ormond Street Hospital in London where he was clinical lead for neuroblastoma. Dr Morgenstern moved to SickKids in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs, and co-lead of the neuroblastoma service. He is also Medical Director of the Oncology/BMT Clinical Trials Support Unit. Dr Morgenstern’s clinical activities are focussed on neuroblastoma and solid tumour patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in paediatric cancers and the development of precision medicine approaches for paediatric solid tumours.
